Astrazeneca (AZN) said Friday that its fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints in a phase 3 trial to treat asthma.

The British pharmaceutical company said the drug showed statistically significant and clinically meaningful improvements in lung function, compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines.